

Pursuant to 18 V.S. A. § 4635, the following manufacturers must submit reports regarding their justification for the increase in the net cost of the following drugs to DHVA, **no later than Nov. 5, 2018:**

PRODUCT	COMPANY
VANCOCIN HCL	ANI PHARMACEUTICALS
LIDODERM	ENDO PHARMACEUTICALS
STRATTERA	LILLY
PRISTIQ	PFIZER U.S.
ENBREL SURECLICK	AMGEN/IMMUNEX
SEROQUEL XR	ASTRAZENECA
HUMIRA PEN	ABBIEVIE
METHYLPHENIDATE HCL ER	ACTAVIS PHARMA
ODEFSEY	GILEAD